Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: The partial protection relies on interferon gamma producing CD8+ T lymphocyte activation

Vaccine

Volumn 20, Issue 19-20, 2002, Pages 2439-2447

  Rafati, Sima ^a   Kariminia, Amina ^a   Seyde Eslami, Shiva ^a   Narimani, Manijeh ^a   Taheri, Tahere ^a   Lebbatard, Mai ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b INSTITUT PASTEUR   (France)

Author keywords

Immunization; Leishmania; Recombinant cysteine proteinases

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYSTEINE PROTEINASE; GAMMA INTERFERON; IONOMYCIN; LEISHMANIA VACCINE; PHORBOL 13 ACETATE 12 MYRISTATE; POLOXAMER; RECOMBINANT PROTEIN; PROTOZOAL VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL INFECTION; FEMALE; FOOT PAD; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; INOCULATION; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN DETERMINATION; PROVOCATION TEST; SKIN LEISHMANIASIS; SKIN PROTECTION; T LYMPHOCYTE ACTIVATION; THICKNESS; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMAL; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE ENDOPEPTIDASES; FEMALE; INTERFERON TYPE II; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; ANIMALS;

EID: 0037035854     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00189-5     Document Type: Article

References (29)

1. Leishmaniasis
2. Clinical spectrum of leishmaniasis
3. Immunologic mechanism in Leishmania
4. The regulation of immunity to Leishmania major
5. The host response to Leishmania infection
6. IL-4 deficient mice resist infection with Leishmania major
7. The immune response to Leishmania: Mechanism of parasite control and evasion
8. Regulation of protective immunity against Leishmania major in mice
9. IL-4 and IL-4 receptor deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains
10. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice
11. Human and murine immune responses to a novel L. major recombinant protein encoded by members of a multi-copy gene family
12. Effective immunization against cutaneous leishmaniasis with recombinant bacilli Calmette Guerin expressing the Leishmania surface protein gp63
13. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection
14. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis
15. Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans
16. A recombinant Leishmania antigen stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
17. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
18. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
19. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans
20. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
21. + T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis
22. Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major
23. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
24. Vervet monkeys vaccinated with killed Leishmania major parasites and interlukin-12 develop a type 1 immune response but are not protected against challenge infection
25. The potency and durability of DNA and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge
26. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis
27. Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three protein expressed in amastigotes and six adjuvants